Drug Profile
Research programme: Alzheimer's disease therapeutics - Afecta Pharmaceuticals
Alternative Names: AFX-929Latest Information Update: 24 Jun 2008
Price :
$50
*
At a glance
- Originator Afecta Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Alzheimer's disease
Most Recent Events
- 24 Jun 2008 Investigation in Alzheimer's disease in USA (unspecified route)